Intestinal Fistula Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: 01 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 23.68 billion |
|
Revenue forecast in 2031 |
US$ 41.55 billion |
|
Growth Rate |
CAGR of 6.4% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Treatment Type, Route of administration, Distribution Channel, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global intestinal fistula treatment market was valued at US$ 23.68 billion in 2022 and is expected to register a revenue CAGR of 6.4% to reach US$ 41.55 billion by 2031.
Market Fundamentals
An intestinal fistula is an abnormal connection between two parts of the intestine, or between the intestine and another organ. This connection can allow the contents of the intestine to leak into other parts of the body, leading to infection and other complications. Intestinal fistulas can be caused by a variety of factors, including surgery, trauma, inflammation, and infection. Symptoms of an intestinal fistula may include abdominal pain, fever, diarrhea, weight loss, and drainage from the affected area. Diagnosis of an intestinal fistula may involve a physical exam, imaging tests such as CT scans or MRI, and laboratory tests to check for infection or inflammation.
Treatment for intestinal fistulas depends on the location and severity of the fistula, as well as the underlying cause. In some cases, conservative management such as antibiotics, nutritional support, and medication to reduce inflammation can be sufficient. However, in more severe cases, surgical repair or diverting ostomy can be necessary to remove or repair the affected area of the intestine. Endoscopic procedures, such as endoscopic stenting or clipping, can be used to manage and treat certain types of intestinal fistulas. Nutritional support is also essential in the treatment of intestinal fistulas, as patients with this condition often experience malnutrition and dehydration. Medications may be prescribed to manage symptoms, such as pain and inflammation, and to prevent or treat infections that may arise due to the fistula. The treatment plan for intestinal fistulas is typically individualized and may involve a combination of different therapies, depending on the specific needs of the patient.
[678678]
Market Dynamics
The incidence of intestinal fistulas is increasing due to various factors such as Crohn's disease, cancer, infections, and surgery is driving the demand for effective treatment options and is supporting the growth global intestinal fistula treatment market. For instance, according to the Crohn’s & Colitis UK article of March 2022, over half a million individuals i.e., 1 in every 123 individuals in the UK suffer from Crohn’s and Colitis. The development of new medical technologies, such as endoscopic procedures, minimally invasive surgery, and advanced imaging techniques, is driving the growth of the global intestinal fistula treatment market. Additionally, personalized medicine is gaining popularity, as it allows healthcare providers to tailor treatments to individual patients based on their unique characteristics. This is expected to drive the demand for personalized treatments for intestinal fistulas. Reimbursement programs implemented by the major firms to offset healthcare costs would encourage patients to seek proper treatment, hence contributing to the growth of the global intestinal fistula treatment market. Moreover, the increasing healthcare expenditure in developed and developing countries is expected to drive the growth of the global intestinal fistula treatment market.
However, intestinal fistulas can interfere with the body's ability to absorb nutrients from food, which can lead to malnutrition and other health problems. To prevent deficits, patients with intestinal fistulas may require nutritional assistance, which raises treatment costs owing to the use of intravenous or tube feeding. Additionally, high costs associated with research & development, shortage of skilled professionals, and lack of healthcare infrastructure in developing economies are some of the restraints impeding the overall market growth.
Market Ecosystem
The global intestinal fistula treatment market is analyzed from four perspectives: Treatment Type, Route of administration, Distribution Channel, and Region.
Intestinal Fistula Treatment Market by Treatment Type
[976756]
Based on the treatment type, the global intestinal fistula treatment market is segmented into anticholinergic, proton-pump inhibitors, H2-receptor antagonists, anti-diarrheal drugs, and others.
The proton-pump inhibitors segment dominated the market with the principal revenue share in 2022, as they are commonly used in the treatment of intestinal fistulas. PPIs work by reducing the amount of acid produced by the stomach, which can help to reduce inflammation and irritation in the digestive tract. PPIs are often prescribed to manage symptoms such as heartburn and acid reflux, which are common in patients with intestinal fistulas. Additionally, PPIs may be used to reduce the risk of infection in patients with fistulas, as the decreased acidity in the digestive tract can help to prevent the growth of harmful bacteria. These medications are available in both prescription and over-the-counter formulations and are generally considered safe and effective when used as directed by a healthcare provider. These factors contribute to the growth of the proton-pump inhibitors segment.
The H2-receptor antagonists segment accounted for the second-largest share in 2022, owing to fast action and minimal side effects. H2-receptor antagonists are a class of medications that block the action of histamine on the H2 receptors in the stomach, reducing the production of stomach acid. They are commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers, which can be associated with intestinal fistulas. H2-receptor antagonists may be used as part of a comprehensive treatment plan for intestinal fistulas, in combination with other medications such as proton pump inhibitors and antibiotics. They can help to reduce the production of stomach acid, which can help to prevent further damage to the intestinal lining and reduce symptoms such as pain and inflammation. The H2-receptor antagonists segment in the intestinal fistula treatment market includes a range of products, such as ranitidine, famotidine, and cimetidine. These medications are typically administered orally, although they may also be given intravenously in certain situations. These factors attribute to the growth of the H2-receptor antagonists segment.
Intestinal Fistula Treatment Market by Route of Administration
Based on the route of administration, the global intestinal fistula treatment market is bifurcated into oral, rectal, and parenteral.
The oral route segment dominated the market with the largest revenue share in 2022, due to the convenience and ease of administration associated with oral medications. The oral route refers to medications that are administered by mouth, typically in the form of tablets, capsules, or liquids. Many medications used to treat intestinal fistulas, such as proton pump inhibitors and antibiotics, are commonly administered orally. The oral route of administration is preferred by many patients because it is non-invasive and relatively easy to administer. Patients can take medications at home without the need for frequent visits to the hospital or other healthcare facilities. The oral route also offers the advantage of a more gradual and sustained release of medication, which can help manage symptoms and reduce the risk of adverse reactions. These overall factors contribute to the growth of the oral route.
The parenteral route segment accounted for the second largest share in 2022, due to the increasing prevalence of gastrointestinal disorders and the rising demand for effective treatments. The term parenteral refers to medications that are administered by injection or infusion, typically into a vein or muscle. Many medications used to treat intestinal fistulas, such as antibiotics and immunosuppressive drugs, may be administered parenterally. The parenteral route of administration is preferred in certain situations where patients are unable to take medications orally or when a more rapid onset of action is required. Parenteral administration can provide a more immediate and predictable response compared to oral medications, which may be particularly important in the treatment of severe infections or complications associated with intestinal fistulas. The parenteral segment in the intestinal fistula treatment market includes a range of products and services, including injectable medications, infusion pumps, and other medical devices used to administer parenteral treatments. These factors attribute to the growth of the parenteral segment growth.
Intestinal Fistula Treatment Market by Distribution Channel
Based on the distribution channel, the global intestinal fistula treatment type market is segmented into hospital, retail, and online pharmacy.
The hospital pharmacy segment dominated the market with the largest revenue share in 2022, increasing the prevalence of gastrointestinal disorders and the rising demand for effective treatments. Hospital pharmacies are responsible for dispensing medications and other medical supplies to patients receiving care in hospitals. They play a critical role in ensuring that patients receive the correct medications and dosages as prescribed by healthcare providers. In the context of intestinal fistula treatment, hospital pharmacies may be involved in the provision of antibiotics, proton pump inhibitors, immunosuppressive drugs, and other medications used to treat symptoms and complications associated with the condition. They may also provide nutritional supplements and other medical supplies to support the management of the fistula. Hospital pharmacies may work closely with other healthcare providers, such as physicians, nurses, and dietitians, to develop and implement treatment plans for patients with intestinal fistulas. They may also be involved in monitoring patients for adverse drug reactions, drug interactions, and other potential complications associated with medication use. These overarching variables contribute to the hospital pharmacy segment growth.
The online pharmacy segment is expected to be the fastest growing segment throughout the forecast period, owing to doorstep delivery and services offered. Online pharmacies may provide access to medications that are commonly used to treat intestinal fistulas, such as antibiotics and anti-inflammatory drugs. Patients may be able to conveniently order these medications online and have them delivered to their doorstep, saving them time and reducing the need for in-person visits to a pharmacy. They may also provide discounts or other incentives, such as free shipping or loyalty programs, that can make treatment more affordable. Customers can now access a wide range of treatments and medications from the comfort of their own homes and have them delivered to their door. Furthermore, the availability of online consultations and prescription services has made it easier for patients to receive the care they need without having to leave the house. These factors are expected to boost the online pharmacy segment.
Intestinal Fistula Treatment Market by Region
Geographically, the global intestinal fistula treatment market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global intestinal fistula treatment market with the largest revenue share in 2022, attributed to the early adoption of the latest technology, the presence of major key players,and solid reimbursement policies. Additionally, companies across the region are continuously working on launching new and novel medication for the treatment of intestinal fistula which is also helping in the growth of the regional market. For instance, in April 2021, BD (Becton, Dickinson, and Company), a leading global medical technology business, announced that enrolment in the CONNECT-AV post-market monitoring study had commenced and the first patients had been treated. CONNECT-AV is a prospective, single-arm, open-label trial that will monitor WavelinQTM EndoAVF System patients for 24 months. The WavelinQ EndoAVF System is indicated for the creation of an arteriovenous fistula (AVF) using a concomitant ulnar artery and ulnar vein or concomitant radial artery and radial vein in patients with chronic kidney disease who require hemodialysis and have minimum artery and vein diameters of 2.0 mm at the fistula creation site.
Competitive Landscape
Focused research and development (R&D) activities enabled the companies to produce breakthrough medications and a vast pipeline of prospective new treatments, resulting in revenue growth and brand image protection. Businesses use their solid R&D foundation to create breakthrough goods. An established presence boosts clients' trust in a company's product offerings and allows it to create a brand image.
The prominent players operating in the global intestinal fistula treatment market are:
Strategic Developments
The estimated market size of the global intestinal fistula treatment market in 2031 is US$ 41.55 billion.
The revenue CAGR of the intestinal fistula treatment market during the forecast period will be 6.4% from 2023 to 2031.
The incidence of intestinal fistula cases, the increasing popularity of personalized medicine, and the development of new medical technologies are factors driving the growth of the global intestinal fistula treatment market.
The high costs associated with research & development, shortage of skilled professionals, and lack of healthcare infrastructure are factors restricting the global market growth to full potential.
Some prominent players operating in the global intestinal fistula treatment market areAvante Health Solutions, Integra LifeSciences, Angiplast Pvt. Ltd., Medtronic plc, and Gulmaher Surgico among others.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst